Fielder Capital Group LLC Takes Position in The Oncology Institute, Inc. (NASDAQ:TOI)

Fielder Capital Group LLC bought a new position in The Oncology Institute, Inc. (NASDAQ:TOI) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 70,192 shares of the company’s stock, valued at approximately $143,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TOI. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Oncology Institute in the 3rd quarter worth approximately $30,000. WealthShield Partners LLC bought a new stake in Oncology Institute in the fourth quarter worth $49,000. Kent Lake Capital LLC purchased a new stake in Oncology Institute during the third quarter valued at about $257,000. Tiff Advisory Services LLC bought a new position in shares of Oncology Institute during the third quarter valued at about $593,000. Finally, Josh Arnold Investment Consultant LLC lifted its stake in shares of Oncology Institute by 77.4% in the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 1,877,472 shares of the company’s stock valued at $2,647,000 after acquiring an additional 819,321 shares during the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Jefferies Financial Group started coverage on Oncology Institute in a research report on Monday, February 26th. They set a “buy” rating and a $2.50 price target on the stock.

Oncology Institute Trading Down 12.1 %

Shares of NASDAQ TOI traded down $0.13 during mid-day trading on Monday, hitting $0.94. The stock had a trading volume of 336,391 shares, compared to its average volume of 126,128. The business has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $1.75. The Oncology Institute, Inc. has a 1 year low of $0.33 and a 1 year high of $2.66. The company has a debt-to-equity ratio of 1.52, a quick ratio of 3.73 and a current ratio of 4.12. The firm has a market cap of $69.90 million, a P/E ratio of -1.04 and a beta of 0.82.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Wednesday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.10). The firm had revenue of $85.79 million during the quarter, compared to analysts’ expectations of $82.04 million. Oncology Institute had a negative net margin of 24.56% and a negative return on equity of 80.46%. On average, equities analysts anticipate that The Oncology Institute, Inc. will post -0.36 EPS for the current fiscal year.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.